BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACH-1625: Phase IIa data

Top-line data from the first part of an ongoing, double-blind, U.S. Phase IIa trial in 64 patients with chronic HCV genotype 1 infection showed that 81%, 75% and 76% of patients receiving once-daily 200, 400 and 800 mg oral ACH-1625, respectively, in combination with standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) achieved an RVR defined as HCV RNA levels <25 IU/mL at week 4 vs. 20% for placebo...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >